QNTM — Quantum BioPharma Share Price
Last trade - 00:00- $14.37m
- $6.95m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.25 | ||
| Price to Tang. Book | 2.19 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -147.55% | ||
| Return on Equity | -114.92% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | 8.68 | 14.95 | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Quantum BioPharma Ltd. is a Canada-based biopharmaceutical company. The Company is engaged in building a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), it is focused on the research and development of its lead compound, Lucid-MS, which is a patented new chemical entity to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Its unbuzzd beverage is a proprietary formulation of vitamins and minerals to help with liver and brain function for the purposes of relieving the effects of alcohol consumption and restoring a normal lifestyle. It maintains a portfolio of strategic investments through its wholly owned subsidiary, FSD Strategic Investments Inc., which represents loans secured by residential or commercial property.
Directors
- Zeeshan Saeed CCH
- Anthony Durkacz CCH (39)
- Nathan Coyle CFO
- Sara May CEX
- Huma Qamar SVP
- Sandra Lottes VPR
- Edward Brennan OTH
- Shahzad Shah OTH
- Donal Carroll DRC
- Fernando Cugliari DRC
- Nitin Kaushal DRC
- Lawrence Latowsky DRC
- Adnan Bashir IND
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 1st, 1998
- Public Since
- May 29th, 2018
- No. of Employees
- 10
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 2,299,760
- Address
- 55 University Ave. , Suite 1003, TORONTO, M5J 2H7
- Web
- https://www.fsdpharma.com/
- Phone
- +1 4168548884
- Auditors
- MNP LLP
Upcoming Events for QNTM
Similar to QNTM
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
As of Today at 22:48 UTC, shares in Quantum BioPharma are trading at $6.30. This share price information is delayed by 15 minutes.
Shares in Quantum BioPharma last closed at $6.30 and the price had moved by -78.98% over the past 365 days. In terms of relative price strength the Quantum BioPharma share price has underperformed the S&P500 Index by -80.23% over the past year.
The overall consensus recommendation for Quantum BioPharma is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreQuantum BioPharma does not currently pay a dividend.
Quantum BioPharma does not currently pay a dividend.
Quantum BioPharma does not currently pay a dividend.
To buy shares in Quantum BioPharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $6.30, shares in Quantum BioPharma had a market capitalisation of $14.37m.
Here are the trading details for Quantum BioPharma:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: QNTM
Based on an overall assessment of its quality, value and momentum Quantum BioPharma is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Quantum BioPharma is $12.80. That is 103.17% above the last closing price of $6.30.
Analysts covering Quantum BioPharma currently have a consensus Earnings Per Share (EPS) forecast of -$1.54 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Quantum BioPharma. Over the past six months, its share price has underperformed the S&P500 Index by -7.53%.
As of the last closing price of $6.30, shares in Quantum BioPharma were trading +11.89% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Quantum BioPharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $6.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Quantum BioPharma's management team is headed by:
- Zeeshan Saeed - CCH
- Anthony Durkacz - CCH
- Nathan Coyle - CFO
- Sara May - CEX
- Huma Qamar - SVP
- Sandra Lottes - VPR
- Edward Brennan - OTH
- Shahzad Shah - OTH
- Donal Carroll - DRC
- Fernando Cugliari - DRC
- Nitin Kaushal - DRC
- Lawrence Latowsky - DRC
- Adnan Bashir - IND